Vanguard Group
ARTV

Vanguard Group’s Artiva Biotherapeutics ARTV Stock Holding History

Vanguard Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.06M Buy
246,006
+86,888
+55% +$328K ﹤0.01% 3768
2025
Q3 		$457K Sell
159,118
-73,854
-32% -$198K ﹤0.01% 3973
2025
Q2 		$352K Sell
232,972
-625,242
-73% -$1.31M ﹤0.01% 3993
2025
Q1 		$2.57M Sell
858,214
-8,711
-1% -$47K ﹤0.01% 3403
2024
Q4 		$8.74M Buy
866,925
+25,920
+3% +$311K ﹤0.01% 3028
2024
Q3 		$13M Buy
+841,005
New +$9.75M ﹤0.01% 2822

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Vanguard Group's ARTV Position: Q4 2025 in Review

Vanguard Group increased its Artiva Biotherapeutics (ARTV) stake by 55% in Q4 2025, buying an estimated $328K and bringing the position to 246,006 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3768.

Vanguard Group first reported a position in ARTV in Q3 2024 and has held it in 6 quarters since. The position peaked at $13M in Q3 2024. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • Vanguard Group held 246,006 shares of Artiva Biotherapeutics worth $1.06M as of Q4 2025.
  • Vanguard Group bought 86,888 Artiva Biotherapeutics shares in Q4 2025, an estimated $328K.
  • Artiva Biotherapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3768 holding.
  • Vanguard Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 6 quarters since.
  • Vanguard Group's Artiva Biotherapeutics position peaked at $13M in Q3 2024.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.